Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

被引：0
|
作者：
Mohamed Hamidou
Antoine Néel
Joel Poupon
Zahir Amoura
Mikael Ebbo
Jean Sibilia
Jean-Francois Viallard
Benjamin Gaborit
Christelle Volteau
Jean Benoit Hardouin
Eric Hachulla
François Rieger
机构：
[1] Department of Internal Medicine,Department of Biological Toxicology
[2] CHU Nantes,Department of Internal Medicine 2, Centre National de Référence pour le Lupus, Institut E3M
[3] Nantes Université,Service de Médecine Interne
[4] AP-HP,Department of Rheumatology
[5] Lariboisière Hospital,Department of Internal Medicine
[6] University Paris VII,Plateforme de Méthodologie et Biostatistiques, CHU Nantes
[7] Hôpital Pitié-Salpétrière,Department of Internal Medicine, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord
[8] Aix Marseille Univ,Ouest de France (CeRAINO)
[9] APHM,undefined
[10] CNRS,undefined
[11] INSERM,undefined
[12] CIML,undefined
[13] Hôpital de la Timone,undefined
[14] University of Strasbourg,undefined
[15] Haut-Lévêque University Hospital,undefined
[16] Université de Nantes,undefined
[17] INSERM UMR 1246-SPHERE,undefined
[18] Université de Nantes,undefined
[19] University of Lille,undefined
[20] MEDSENIC,undefined
[21] SAS,undefined
[22] a company with CNRS participation,undefined
来源：
Arthritis Research & Therapy | / 23卷
关键词：
Systemic lupus erythematosus; Autoimmune diseases; Treatment; Arsenic trioxide; Phase II clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)
    Hamidou, Mohamed
    Neel, Antoine
    Poupon, Joel
    Amoura, Zahir
    Ebbo, Mikael
    Sibilia, Jean
    Viallard, Jean-Francois
    Gaborit, Benjamin
    Volteau, Christelle
    Hardouin, Jean Benoit
    Hachulla, Eric
    Rieger, Francois
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [2] EFFICACY OF BROMOCRIPTINE IN AN OPEN-LABEL THERAPEUTIC TRIAL FOR SYSTEMIC LUPUS-ERYTHEMATOSUS
    MCMURRAY, RW
    WEIDENSAUL, D
    ALLEN, SH
    WALKER, SE
    JOURNAL OF RHEUMATOLOGY, 1995, 22 (11) : 2084 - 2091
  • [3] Low-dose intravenous immunoglobulin therapy in systemic lupus erythematosus
    Sherer, Y.
    Levy, Y.
    Sabine, K.
    Scali, J.
    Rovensky, J.
    Goddard, G.
    Shoenfeld, Y.
    ALLERGY, 2007, 62 : 496 - 496
  • [4] Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study
    Aringer, M
    Graninger, WB
    Steiner, GN
    Smolen, JS
    ARTHRITIS AND RHEUMATISM, 2004, 50 (10): : 3161 - 3169
  • [5] Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus
    Emma Jane MacDermott
    Thomas J. A. Lehman
    Current Rheumatology Reports, 2006, 8 (6) : 439 - 440
  • [6] Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study
    van Vollenhoven, Ronald F.
    Hahn, Bevra H.
    Tsokos, George C.
    Lipsky, Peter
    Gordon, Robert M.
    Fei, Kaiyin
    Lo, Kim Hung
    Chevrier, Marc
    Rose, Shawn
    Berry, Pamela
    Yao, Zhenling
    Karyekar, Chetan S.
    Zuraw, Qing
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (04) : 380 - 387
  • [7] EFFICACY AND SAFETY OF LOW-DOSE IL-2 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Su, Q. Y.
    Luo, J.
    Di, J. K.
    Yin, X. Y.
    Xu, D. N.
    Li, X.
    Wang, C.
    Zhang, S. X.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 640 - 641
  • [8] Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus
    Guan, Xin
    Zhao, Zerui
    Xia, Guangtao
    Xin, Miaomiao
    Yang, Qingrui
    Sun, Hongling
    Fu, Min
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (07) : 1399 - 1402
  • [9] Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
    Chatham, W. Winn
    Furie, Richard
    Saxena, Amit
    Brohawn, Philip
    Schwetje, Erik
    Abreu, Gabriel
    Tummala, Raj
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 837 - 847
  • [10] Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
    Zhang, Jing
    Wan, Weiguo
    Miao, Liyan
    Wu, Jian
    Dong, Jun
    Shen, Yinghua
    Xiong, Cui
    Li, Chao
    Xue, Yu
    Cao, Guoying
    Ma, Peiming
    RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 191 - 200
12345